Drug Profile
INCB 19602
Alternative Names: INCB019602; INCB19602Latest Information Update: 24 May 2010
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Class Antihyperglycaemics
- Mechanism of Action GPR109A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 31 May 2008 Phase-II clinical trials in Type-2 diabetes mellitus in USA (PO)
- 30 Apr 2008 Incyte completes phase I trials in Type-2 diabetes in USA
- 08 Jan 2008 Phase-I clinical trials in Type-2 diabetes mellitus in USA (PO)